1. "Thoracic Oncology"
  2. "Naiyer Rizvi"
Formats
  1. Journal Article (48)
  2. Meeting Abstract (48)
  3. Research Letter (1)
Groups
  1. Department of Medicine (97)
  2. Solid Tumor Oncology Division (97)
  3. Thoracic Oncology (97)
  4. Radiology, Department of (30)
  5. Body Imaging Service (28)
  6. GSK Faculty (25)

More Groups

People
  1. Naiyer Rizvi (97)
  2. Mark Kris (71)
  3. Christopher Azzoli (37)
  4. Vincent Miller (37)
  5. Lee Krug (31)
  6. Gregory Riely (30)

More People

Years
  1. 2019 (1)
  2. 2018 (2)
  3. 2017 (4)
  4. 2016 (4)
  5. 2015 (11)
  6. 2014 (5)

More Years

Publications
  1. Journal of Clinical Oncology (35)
  2. Journal of Thoracic Oncology (23)
  3. Clinical Cancer Research (8)
  4. Cancer Chemotherapy and Pharmacology (7)
  5. Cancer (4)
  6. Lung Cancer (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (35)
  2. Elsevier Inc. (26)
  3. American Association for Cancer Research (10)
  4. Springer (7)
  5. Wiley Blackwell (5)
  6. Elsevier Ireland Ltd. (4)

More Publishers

Results (97)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types
    Research Letter

    Samstein, R. M.; Lee, C. H.; Shoushtari, A. N.; Hellmann, M. D.; Shen, R.; Janjigian, Y. Y.; Barron, D. A.; Zehir, A.; Jordan, E. J.; Omuro, A.; more...
    Nature Genetics (2019)

    Fulltext@MSK | Save
  • Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors
    Meeting Abstract

    Wu, J.; Freites-Martinez, A.; Hellmann, M. D.; Rosenberg, J. E.; Motzer, R. J.; Chapman, P. B.; Rizvi, N. A.; Geskin, L. J.; Reed, V. A.; Dusza, S. W.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC
    Journal Article

    Gettinger, S.; Hellmann, M. D.; Chow, L. Q. M.; Borghaei, H.; Antonia, S.; Brahmer, J. R.; Goldman, J. W.; Gerber, D. E.; Juergens, R. A.; Shepherd, F. A.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • First-line nivolumab monotherapy and nivolumab plus ipilimumab in patients with advanced NSCLC: Long-term outcomes from CheckMate 012
    Meeting Abstract

    Gettinger, S.; Rizvi, N.; Chow, L.; Borghaei, H.; Brahmer, J.; Shepherd, F.; Ready, N.; Gerber, D.; Antonia, S.; Goldman, J. W.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)
    Journal Article

    Horn, L.; Spigel, D. R.; Vokes, E. E.; Holgado, E.; Ready, N.; Steins, M.; Poddubskaya, E.; Borghaei, H.; Felip, E.; Paz-Ares, L.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)
    Journal Article

    Peters, S.; Gettinger, S.; Johnson, M. L.; Jänne, P. A.; Garassino, M. C.; Christoph, D.; Toh, C. K.; Rizvi, N. A.; Chaft, J. E.; Costa, E. C.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): Results of an open-label, phase 1, multicohort study
    Journal Article

    Hellmann, M. D.; Rizvi, N. A.; Goldman, J. W.; Gettinger, S. N.; Borghaei, H.; Brahmer, J. R.; Ready, N. E.; Gerber, D. E.; Chow, L. Q.; Juergens, R. A.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • Long-term outcomes with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update
    Meeting Abstract

    Barlesi, F.; Steins, M.; Horn, L.; Ready, N.; Felip, E.; Borghaei, H.; Spigel, D. R.; Arrieta, O.; Antonia, S. J.; Fayette, J.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • CheckMate 017 and 057 studies of nivolumab vs docetaxel in patients with advanced NSCLC: 2-year-update and exploratory cytokine profile analyses
    Meeting Abstract

    Eberhardt, W. E. E.; Borghaei, H.; Brahmer, J. R.; Horn, L.; Ready, N.; Steins, M.; Felip, E.; Paz-Ares, L. G.; Arrieta, O.; Barlesi, F.; more...
    Oncology Research and Treatment (2016)

    Fulltext@MSK | Save
  • Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer
    Journal Article

    Rizvi, N. A.; Hellmann, M. D.; Brahmer, J. R.; Juergens, R. A.; Borghaei, H.; Gettinger, S.; Chow, L. Q.; Gerber, D. E.; Laurie, S. A.; Goldman, J. W.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save